Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/11/2022 | Neutral → Underweight | JP Morgan | |
| 3/29/2022 | Overweight → Neutral | JP Morgan | |
| 3/4/2022 | $9.00 → $3.00 | Outperform → Sector Perform | RBC Capital |
| 3/3/2022 | $4.00 → $2.00 | Underweight | Morgan Stanley |
| 3/3/2022 | $5.00 → $3.50 | Neutral | Goldman Sachs |
| 3/3/2022 | $5.50 → $4.00 | Overweight | Barclays |
| 3/3/2022 | $10.00 → $5.00 | Overweight | Piper Sandler |
| 3/2/2022 | Buy → Underperform | BofA Securities |
Q3'23 Revenue from Continuing Business of $269.4 million, up 39% year over year Value-Based Consumers served of 355,000, an increase of 208.7% on a comparable basis from last year on strong growth in Care Delivery Q3'23 Net Loss from Continuing Business of $479.3 million, including a $401.4 million non-cash Goodwill impairment charge; Positive Adjusted EBITDA of $1.2 million in Q3'23 Maintaining expectation for 2023 consolidated Adjusted EBITDA profitability† Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today reported financial r
Bright Health Group, Inc. ("Bright Health") (NYSE:BHG), the technology enabled, value-driven healthcare company, today announced it will report Third Quarter financial results before the financial markets open on Tuesday, November 7, 2023, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via Bright Health's Investor Relations page at investors.brighthe
Q2'23 Revenue from Continuing Business of $298.0 million, up 100% year over year Value-Based Consumers served of 371,000, an increase of 214% on a comparable basis from last year on strong growth in Care Delivery Q2'23 Net Loss from Continuing Business of $31.7 million; Positive Adjusted EBITDA of $6.4 million in Q2'23, positive Operating Income in Care Delivery and Care Solutions segments Maintaining expectation for 2023 consolidated Adjusted EBITDA profitability† Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today reported fi
The Company will advance its value-driven, consumer-centric care model through its owned and affiliated clinics and provider enablement services Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG) today announced that it has adopted NeueHealth as its corporate brand name. This reflects the Company's ongoing focus on its NeueHealth business, which will continue driving long-term sustainable growth of its value-driven, consumer-centric care model, thereby increasing access to high-quality healthcare for all populations across the ACA Marketplace, Medicare, and Medicaid. The Company's common stock will begin trading under the new ticker symbol "NEUE" on the New York Stock
Completes final repayment on secured credit facility eliminating the Company's secured debt Further focuses on increasing access to value-driven healthcare for all populations across the ACA Marketplace, Medicare, and Medicaid through its continuing business, NeueHealth Reaffirms expectation for Adjusted EBITDA profitability in 2024 Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company, today announced that it has successfully completed the sale of its California Medicare Advantage business, Brand New Day and Central Health Plan, to Molina Healthcare, Inc. ("Molina"). The sale closed, effective as of Januar
Received all required regulatory approvals on the sale of the California Medicare Advantage business; the transaction is expected to close on or about January 1, 2024 Amended Company's secured credit facility to reduce the final repayment resulting in approximately $30 million in savings Meaningfully improves capital position to support continuing business, NeueHealth, a value-driven consumer care delivery and provider enablement business Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company, today announced that it entered into an amendment to its credit facility with J.P. Morgan that will reduce the final
8-K - Bright Health Group Inc. (0001671284) (Filer)
8-K - Bright Health Group Inc. (0001671284) (Filer)
8-K - Bright Health Group Inc. (0001671284) (Filer)
JP Morgan downgraded Bright Health Group from Neutral to Underweight
JP Morgan downgraded Bright Health Group from Overweight to Neutral
RBC Capital downgraded Bright Health Gr from Outperform to Sector Perform and set a new price target of $3.00 from $9.00 previously
4 - Bright Health Group Inc. (0001671284) (Issuer)
4 - Bright Health Group Inc. (0001671284) (Issuer)
4 - Bright Health Group Inc. (0001671284) (Issuer)
Cathy Smith to Step Down to Pursue New Opportunity, Effective May 12, 2023 Bright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG), the technology enabled, value-driven healthcare company serving aging and underserved consumers with unmet clinical needs, today announced that it has appointed Jay Matushak as the Company's next Chief Financial Officer, effective May 12, 2023. Mr. Matushak will succeed Cathy Smith, who is stepping down to pursue another opportunity. Mr. Matushak, a seasoned finance and operational executive with deep expertise in the healthcare business, joined Bright Health in 2021. He currently serves as Senior Vice President of Finance and is responsible
Jeff Craig, lead counsel for the Company's NeueHealth business, named General Counsel and Corporate Secretary Bright Health Group, Inc. ("Bright Health" or "The Company") (NYSE:BHG), the first technology-enabled, Fully Aligned system of care built for healthcare's consumer retail market, today announced that Keith Nelsen will retire as General Counsel and Corporate Secretary. Jeff Craig, lead counsel for the Company's NeueHealth business, will be promoted to the role of General Counsel and Corporate Secretary effective March 18, 2022. Nelsen will stay on as a senior advisor with the Company until June 30, 2022, to ensure a smooth transition. "Keith has been a key leader for many of our mi
Matthew Manders to Join as Independent Director Bright Health Group, Inc. ("Bright Health") (NYSE:BHG), the first technology-enabled, Fully Aligned system of care built for healthcare's consumer retail market, today announced that leading healthcare expert Matt Manders will join the company's Board as an independent director, effective March 1. Manders brings a wealth of diverse healthcare experience, focus on operational excellence, and expertise in consumer-driven healthcare. Most recently, he served as president of Cigna Corporation's Government and Solutions organization, part of a 30-plus-year career with the company. In this role, Manders led and managed Cigna's U.S. Government busi
SC 13G/A - NeueHealth, Inc. (0001671284) (Subject)
SC 13D/A - NeueHealth, Inc. (0001671284) (Subject)
SC 13D/A - Bright Health Group Inc. (0001671284) (Subject)
The Company will advance its value-driven, consumer-centric care model through its owned and affiliated clinics and provider enablement servicesBright Health Group, Inc. ("Bright Health" or the "Company") (NYSE:BHG) today announced that it has adopted NeueHealth as its corporate brand name. This reflects the Company's ongoing focus on its NeueHealth business, which will continue driving long-term sustainable growth of its value-driven, consumer-centric care model, thereby increasing access to high-quality healthcare for all populations across the ACA Marketplace, Medicare, and Medicaid. The Company's common stock will begin trading under the new ticker symbol "NEUE" on the New York Stock Exc
Shares of RxSight, Inc. (NASDAQ:RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41. RxSight shares jumped 20% to $44.31 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Harpoon Therapeutics, Inc. (NASDAQ:HARP) shares jumped 111.2% to $22.28 after Merck announced it will acquire the company for $23 per share in cash. Ambrx Biopharma Inc. (NASDAQ:AMAM) jumped 98.1% to $27.00 after Johnson & Johnson announced it will acquire the company in an all-cash merger for a total equity value
Gainers Omega Therapeutics (NASDAQ:OMGA) shares increased by 99.6% to $5.45 during Thursday's regular session. The market value of their outstanding shares is at $300.5 million. Avenue Therapeutics (NASDAQ:ATXI) shares increased by 56.08% to $0.27. The company's market cap stands at $3.6 million. Dyne Therapeutics (NASDAQ:DYN) stock rose 30.28% to $19.24. The market value of their outstanding shares is at $1.1 billion. Adicet Bio (NASDAQ:ACET) shares moved upwards by 25.0% to $2.2. The company's market cap stands at $94.9 million. Bright Health Gr (NYSE:BHG) stock increased by 24.15% to $11.36. The company's market cap stands at $90.6 million. Werewolf Therapeutics (NASDAQ:HOWL) shares